Literature DB >> 9200705

Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate.

T L Hughes1, T M Hahn, K K Reynolds, D S Shewach.   

Abstract

Deoxycytidine kinase is the rate-limiting process in the activation for several clinically important antitumor agents. Previous studies have focused on deoxycytidine (dCyd) and adenosine triphosphate (ATP) as substrates for this enzyme. In view of recent data indicating that uridine triphosphate (UTP) is the physiologic phosphate donor for this enzyme, a study of the kinetic properties of dCyd kinase with dCyd and UTP was undertaken. The results presented here demonstrate that UTP and ATP produce kinetically distinguishable differences in nucleoside phosphorylation by dCyd kinase. At high dCyd concentrations, dCyd kinase exhibited substrate activation with ATP. In contrast, in the presence of UTP, substrate inhibition was observed at concentrations of dCyd greater than 3 microM. Inhibition by dCyd was noncompetitive with respect to UTP and could not be reversed by a 200-fold increase in UTP concentration, indicating that the inhibition was not due to dCyd binding at the nucleotide binding site. The kinetic mechanism for dCyd kinase was determined with dCyd and UTP as substrates. UTP was the preferred phosphate donor with a true Km value of 1 microM compared to 54 microM with ATP, resulting in a 50-fold greater substrate efficiency for UTP. Although the double-reciprocal plots with UTP produced parallel lines, initial velocity plots with other phosphate donors and product inhibition studies indicated that dCyd kinase formed a ternary complex with its substrates. The parallel lines with UTP were apparently due to a low dissociation constant for UTP, which was calculated as more than 13-fold lower than its Km value. Analysis of product inhibition studies indicated that dCyd kinase followed an ordered A-B random P-Q reaction sequence, with UTP as the first substrate to bind. In contrast, previous results demonstrated a random bi-bi sequence for dCyd kinase in the presence of ATP. The combined results indicate that the enzyme can follow a random bi-bi reaction sequence, but with UTP as the phosphate donor, the addition of nucleotide prior to dCyd is strongly preferred. The noncompetitive substrate inhibition, which was independent of UTP concentration, indicates that high concentrations of dCyd promote addition of the nucleoside prior to UTP, resulting in a lower velocity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200705     DOI: 10.1021/bi970059r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Antiviral guanosine analogs as substrates for deoxyguanosine kinase: implications for chemotherapy.

Authors:  A Herrström Sjöberg; L Wang; S Eriksson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release.

Authors:  Saugata Hazra; Andrzej Szewczak; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2011-03-16       Impact factor: 3.162

Review 3.  Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Authors:  Vanja Vaccaro; Isabella Sperduti; Sabrina Vari; Emilio Bria; Davide Melisi; Carlo Garufi; Carmen Nuzzo; Aldo Scarpa; Giampaolo Tortora; Francesco Cognetti; Michele Reni; Michele Milella
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

4.  Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

5.  Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.

Authors:  Simone Limmer; Jasmin Hahn; Rebecca Schmidt; Kirsten Wachholz; Anja Zengerle; Katharina Lechner; Hansjörg Eibl; Rolf D Issels; Martin Hossann; Lars H Lindner
Journal:  Pharm Res       Date:  2014-03-06       Impact factor: 4.200

6.  Structural basis for substrate promiscuity of dCK.

Authors:  Elisabetta Sabini; Saugata Hazra; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  J Mol Biol       Date:  2008-03-03       Impact factor: 5.469

Review 7.  Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.

Authors:  Jiqing Xie; Jing Yuan; Laichun Lu
Journal:  Diagn Pathol       Date:  2014-11-25       Impact factor: 2.644

8.  Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Authors:  Kahina Hammam; Magali Saez-Ayala; Etienne Rebuffet; Laurent Gros; Sophie Lopez; Berengere Hajem; Martine Humbert; Emilie Baudelet; Stephane Audebert; Stephane Betzi; Adrien Lugari; Sebastien Combes; Sebastien Letard; Nathalie Casteran; Colin Mansfield; Alain Moussy; Paulo De Sepulveda; Xavier Morelli; Patrice Dubreuil
Journal:  Nat Commun       Date:  2017-11-10       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.